Sarah specializes in studying the impact of industries like food and tobacco on the mental and physical health of Americans. Her interests include ultra-processed foods, smokeless tobacco, and health trends like menopausal health products and peptides. You can message her anonymously via Signal at sarahlizchar.47.
Lizzie is responsible for STAT’s coverage of the FDA. Her reporting explores the intersection between FDA policy and science, the implications for industry, and the agency’s ability to protect and promote public health.
This is a victory for proponents of peptide drugs and for Secretary of Health and Human Services Robert F. Kennedy Jr. On Thursday, a U.S. Food and Drug Administration advisory panel recommended allowing pharmacies to manufacture BPC-157, KPV, TB-500, and MOTS-c.
These decisions are non-binding, and the FDA will ultimately decide whether to lift the existing restrictions on these peptide drugs and make them more accessible to those who rely on these less-studied but popular medications to improve their health. The FDA typically does not go against the recommendations of the Pharmaceutical Preparation Advisory Committee (PCAC), but this has happened at least once.
Sarah specializes in studying the impact of industries like food and tobacco on the mental and physical health of Americans. Her interests include ultra-processed foods, smokeless tobacco, and health trends like menopausal health products and peptides. You can message her anonymously via Signal at sarahlizchar.47.
Lizzie is responsible for STAT’s coverage of the FDA. Her reporting explores the intersection between FDA policy and science, the implications for industry, and the agency’s ability to protect and promote public health.
We will process your data in accordance with our privacy policy and terms of service. You can unsubscribe from urgent communications at any time.
Post time: Oct-12-2026